If the results of a Phase III trial are positive, the data is submitted to regulatory agencies, such as the FDA or the EMA, for review. If approved, the new treatment can become a new standard of care for patients with the specific type of cancer studied. In some cases, additional Phase IV trials may be conducted after approval to gather more information on the treatment's long-term safety and effectiveness in a broader patient population.
